5 Biotechnology Stocks to Buy Now

ARIA, NBIX, ARRY, CLDX, INSM improve in weekly rankings

   
5 Biotechnology Stocks to Buy Now

The grades of five Biotechnology stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).

Ariad Pharmaceuticals (NASDAQ:ARIA) ups its rating to a B (“buy”) this week after earning a C (“hold”) in the week before. ARIAD Pharmaceuticals is an oncology company that focuses on the discovery, development, and commercialization of medicines for cancer patients. For more information, get Portfolio Grader’s complete analysis of ARIA stock.

This is a strong week for Neurocrine Biosciences (NASDAQ:NBIX). The company’s rating climbs to B from the previous week’s C. Neurocrine Biosciences is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. Shares of NBIX have increased 5.5% over the past month, better than the 3.9% increase the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of NBIX stock.

This week, Array BioPharma (NASDAQ:ARRY) pushes up from a C to a B rating. Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. Investors seem to agree with the upgraded status of the stock, and have pushed the stock up 25.1% over the past month. For more information, get Portfolio Grader’s complete analysis of ARRY stock.

Celldex Therapeutics (NASDAQ:CLDX) is progressing from last week’s rating of B (“buy”) as the company improves to an A (“strong buy”) this week. Celldex Therapeutics is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. Investors have pushed the stock price up 20% over the past month. For more information, get Portfolio Grader’s complete analysis of CLDX stock.

Insmed Inc. (NASDAQ:INSM) boosts its rating from a C to a B this week. Insmed develops and commercializes drugs that treat metabolic diseases, endocrine disorders and oncology. Wall Street has pushed the stock higher by 23.4% over the past month. For more information, get Portfolio Grader’s complete analysis of INSM stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, http://investorplace.com/2013/03/5-biotechnology-stocks-to-buy-now-aria-nbix-arry-3/.

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.